Lipocine Reports Financial Turnaround for 2024 Lipocine achieved profitability in 2024, reporting $8,400 in net income versus a $16.4M loss in 2023. Revenue of $11.2M, driven by licensing deals, highlights strategic progress. With a strong cash position of $21.6M and reduced R&D expenses, the company is poised for future pipeline advancements despite ongoing regulatory hurdles.453